SOURCE: BioMedReports

BiomedReports

May 04, 2010 15:11 ET

Revolutionary Glucose Breath Test Attracting Potential Partners

LOS ANGELES, CA--(Marketwire - May 4, 2010) -  PositiveID Corporation (NASDAQ: PSID) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge diabetic market that the test would open up.

As reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a diabetic patient's exhaled breath.

It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company's patent-pending technology.

Industry sources say a significant partnership may be very close to completion and public announcement. Such news would not only help validate the technology, but would also likely send PSID's tightly floated shares upward.

In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device could eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading.

Trade alert report with more details is available at BioMedReports.Com
http://biomedreports.com/articles/most-popular/38822-postive-news-coming-for-glucose-breath-test.html

Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

About BioMedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to http://BioMedReports.com

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556